source
- Viridian's elegrobart shows strong results in chronic thyroid eye disease trial, challenging Amgen's TepezzaViridian Therapeutics announced that its injectable drug elegrobart met its primary goals in a late-stage study of patients with chronic thyroid eye disease. The trial reported response rates of 50…
- Cytospire secures $83 million to develop pan-gamma delta T-cell engagersCytospire, a British biotechnology startup, announced it raised £61 million, about $83 million, to fund the development of a new type of T-cell engager therapy. The company is targeting a "pan-gam…